- Home
- LUNG vs HLVX Comparison
LUNG vs HLVX Comparison
Compare LUNG & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- HLVX
- Stock Information
- Founded
- LUNG 1995
- HLVX 2020
- Country
- LUNG United States
- HLVX United States
- Employees
- LUNG N/A
- HLVX N/A
- Industry
- LUNG Industrial Specialties
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- HLVX Health Care
- Exchange
- LUNG Nasdaq
- HLVX Nasdaq
- Market Cap
- LUNG 106.3M
- HLVX 105.2M
- IPO Year
- LUNG 2020
- HLVX 2022
- Fundamental
- Price
- LUNG $3.09
- HLVX $2.11
- Analyst Decision
- LUNG Buy
- HLVX Hold
- Analyst Count
- LUNG 6
- HLVX 1
- Target Price
- LUNG $11.53
- HLVX $2.00
- AVG Volume (30 Days)
- LUNG 408.2K
- HLVX 134.1K
- Earning Date
- LUNG 07-30-2025
- HLVX 08-07-2025
- Dividend Yield
- LUNG N/A
- HLVX N/A
- EPS Growth
- LUNG N/A
- HLVX N/A
- EPS
- LUNG N/A
- HLVX N/A
- Revenue
- LUNG $87,473,000.00
- HLVX N/A
- Revenue This Year
- LUNG $18.02
- HLVX N/A
- Revenue Next Year
- LUNG $18.17
- HLVX N/A
- P/E Ratio
- LUNG N/A
- HLVX N/A
- Revenue Growth
- LUNG 19.84
- HLVX N/A
- 52 Week Low
- LUNG $2.50
- HLVX $1.34
- 52 Week High
- LUNG $9.37
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- LUNG 50.76
- HLVX 56.10
- Support Level
- LUNG $3.03
- HLVX $2.07
- Resistance Level
- LUNG $3.88
- HLVX $2.17
- Average True Range (ATR)
- LUNG 0.34
- HLVX 0.07
- MACD
- LUNG 0.05
- HLVX -0.00
- Stochastic Oscillator
- LUNG 39.23
- HLVX 60.00
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.